Exercise program for breast cancer survivors
Indoor Rowing as a Novel Exercise Therapy for Cardiovascular Rehabilitation in Middle-Aged and Older Breast Cancer Survivors Following Chemotherapy
This study tests whether a rowing exercise program can help breast cancer survivors improve their heart health after finishing treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | Female |
| Sponsor | University of Florida Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT05848141 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a novel exercise intervention specifically designed for breast cancer survivors who have completed their treatment. It aims to assess how rowing as a form of cardiovascular rehabilitation can reduce the risk of cardiovascular disease in this population. Participants will engage in structured exercise training to evaluate improvements in their cardiovascular health. The study focuses on women aged 40 to 80 who have been cancer-free for 6 to 24 months after treatment.
Who should consider this trial
Good fit: Ideal candidates are female breast cancer survivors aged 40 to 80 who have completed their treatment within the last 6 to 24 months.
Not a fit: Patients currently undergoing treatment for breast cancer or those with advanced lymphedema may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce cardiovascular disease risk among breast cancer survivors.
How similar studies have performed: Other studies have shown positive outcomes with exercise interventions in cancer survivors, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of primary invasive non-metastatic breast cancer, stages I-III * female based on biological sex * 40 to 80 years of age * completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation * absence of contraindications to exercise or study participation * study clinician approval Exclusion Criteria: * do not meet inclusion criteria * receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation * lymphedema stage ≥ 2 prior to study enrolment * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss) * consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months
Where this trial is running
Gainesville, Florida
- Integrative Cardiovasculal Physiology Laboratory, University of Florida — Gainesville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Demetra Christou, PhD — University of Florida
- Study coordinator: Demetra Christou, PhD
- Email: ddchristou@ufl.edu
- Phone: 352-294-1746
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.